Elevance Health 8-K
Guidance reaffirmed
FY2026 outlook reaffirmed for investor meetings: EPS of at least $22.00 diluted and $29.00 adjusted.
Filed 2026-11-10 16:30 ET
- 7.01 Regulation FD Disclosure
Summary
Full-year 2026 guidance reaffirmation. Elevance Health officers will reaffirm the outlook during investor and analyst meetings this week: diluted shareholders’ earnings of at least $22.00, including ≈$7.00 per share of net unfavorable items, and adjusted shareholders’ earnings of at least $29.00. The adjusted outlook excludes those items and no other adjustments beyond those reported in Q3 2026.
Guidance
| Metric | Period | Guidance | Prior | Direction |
|---|---|---|---|---|
| Diluted shareholders’ earnings | FY2026 | At least $22.00 per share, including ≈$7.00 per share of net unfavorable items | — | Reaffirmed |
| Adjusted shareholders’ earnings | FY2026 | At least $29.00 per share | — | Reaffirmed |
| Benefit expense ratio | FY2026 | 90.2% ± 50 bp | — | Reaffirmed |
The summary is written by an AI model reading the filing.
Model 005 · prompt v192 · 2026-11-10 23:35:29Z